BRIEF-Toray Industries received FDA approval to begin clinical trials of cancer drug candidate in U.S.- Nikkei
* Toray Industries received FDA approval to begin clinical trials of cancer drug candidate in U.S. allowing testing on human patients- Nikkei Source text for Eikon: Further company coverage:
* Invests 0.3 million euros ($318,330) in diagnostic platform Sistema nCounter Flex of US Nanostring Technologies Source text: http://bit.ly/2lMKSrM Further company coverage: ($1 = 0.9424 euros) (Gdynia Newsroom)
* Total backlog of $133.2 million as of December 31, 2016, representing 23 signed sales contracts
* Neuron Bio to control 92.39 percent of Neol Bio Source text: http://bit.ly/2m32gtr
WASHINGTON, Feb 27 President Donald Trump told several chief executives of large insurance companies on Monday that 2017 will be a "catastrophic" year for the Affordable Care Act as he seeks to make good on a campaign promise to repeal the measure.
No related earnings announcements are currently scheduled within the next 7 days.